Press Releases
View printer-friendly version |
Xtant Medical Announces Record Date and Other Key Dates for Proposed $15 Million Rights Offering
Subject to the registration statement relating to the rights offering becoming effective on or about
The Company expects that subscription materials will be mailed on or about
The expected calendar for the rights offering, unless extended or modified by the Company, is as follows:
November 5, 2020 at5:00 PM , New York City Time: Record DateNovember 6, 2020 : Estimated Distribution Date; Subscription Period Estimated to BeginDecember 4, 2020 at5:00 PM , New York City Time: Expiration Date; Subscription Period EndsDecember 8, 2020 : Estimated Date of Distribution of Common Stock
Important Information
A registration statement on Form S-1 relating to the rights offering has been filed with the
This press release does not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock issuable in the rights offering, nor will there be any sale of such common stock in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Xtant
The symbols ™ and ® denote trademarks and registered trademarks of
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “future,” “will,” “may,” “continue,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s expectations regarding the timing and terms of the rights offering. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: risks and uncertainties surrounding the timing and success of the rights offering including the Company’s ability to cause its registration statement on Form S-1 to become effective in the expected timeframe; the effect of the COVID-19 pandemic on the Company’s business, operating results and financial condition; the Company’s future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended
Investor Relations Contact
Lazar FINN
Ph: 212-867-1762
Email: david.carey@finnpartners.com
Source: Xtant Medical, Inc.